Regado Starts Phase III But Still Needs Help Reaching The Finish Line
This article was originally published in The Pink Sheet Daily
The New Jersey biotech has reached a major milestone in the development of its lead candidate, an anticoagulant, but a shortage of financing has left management searching for a favorable partnering opportunity.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.